Business Daily Media

Times Advertising

.

China Biotech (8037.HK): Anticipating promising results from cell therapy and from precision diagnostics

  • Written by ACN Newswire - Press Releases
HONG KONG, Jun 28, 2021 - (ACN Newswire) - 2021-6-23 / Gelonghui - China Biotech's cell therapy was approved by the NMPA to enter Phase I clinical trials as a Class I new drug, while the recent CAR-T cell therapy approval for product marketing in China means a new era of immune cell therapy has begun.
Source: official website of NMPA
image
China Biotech (8037.HK): Anticipating promising results from cell therapy and from precision diagnostics
China Biotech (8037.HK): Anticipating promising results from cell therapy and from precision diagnostics
According to

Read more //?#

PayNuts Unveils Expanded Integrated Solutions and Refreshed Brand to Support Australian SMEs

PayNuts, one of Australia’s fastest-growing payment service providers, has unveiled a refreshed brand identity and an expanded suite of integrated b...

BizCover Brings Australia’s First AI-Based Insurance Quotes to ChatGPT

Australian small business owners can now receive and compare business insurance quotes directly inside ChatGPT, in a move that signals a major shi...

VistaPrint Research Reveals Australian Small Businesses Face a Succession Cliff

With only 16% of retiring small businesses having a succession plan, tens of thousands risk closure as one in three owners nears retirement.  Ne...

Corporate volunteering grows up: how companies are shifting to meaningful, community-led impact

As workplaces settle into the new year and look for ways to strengthen culture, capability and connection, experts say corporate volunteering is e...

The Rise of Mobile-First Venues

Global Hospitality Platform, Tabit, Reveals Five Ways to Maximise Benefits of Mobile-First Systems  As Australian hospitality venues grapple with...

Why the SME is now the primary engine of global cybercrime

For over a decade, the most practical and effective advice we could offer an employee was to spot the typo. It was practical, it was free, and it wo...